MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review

August 2019 | 52 pages | ID: M130417030AEN
GlobalData

Abstracts

MediGene AG (MDG1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB’s), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US and Europe. Medigene is headquartered in Martinsried, Germany.

MediGene AG Key Recent Developments

Aug 07,2019: Medigene reports financial & business results for the first six months of 2019
May 14,2019: Medigene reports financial & business results for the first three months of 2019
Apr 05,2019: Roivant and Sinovant launch biopharma firm Cytovant Sciences
Apr 02,2019: Medigene presented selective killing of tumor cells by PRAME TCR-transduced T cells at AACR
Mar 19,2019: Medigene presented paths to potential neoantigen-based TCR-therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

MediGene AG - Key Facts
MediGene AG - Key Employees
MediGene AG - Key Employee Biographies
MediGene AG - Major Products and Services
MediGene AG - History
MediGene AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
MediGene AG - Business Description
Business Segment: Immunotherapies (core business)
Overview
Performance
Business Segment: Other products (non-core business)
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Others
Performance
Geographical Segment: United States
Performance
MediGene AG - SWOT Analysis
SWOT Analysis - Overview
MediGene AG - Strengths
MediGene AG - Weaknesses
MediGene AG - Opportunities
MediGene AG - Threats
MediGene AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
MediGene AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Aug 07, 2019: Medigene reports financial & business results for the first six months of 2019
May 14, 2019: Medigene reports financial & business results for the first three months of 2019
Apr 05, 2019: Roivant and Sinovant launch biopharma firm Cytovant Sciences
Apr 02, 2019: Medigene presented selective killing of tumor cells by PRAME TCR-transduced T cells at AACR
Mar 19, 2019: Medigene presented paths to potential neoantigen-based TCR-therapies
Mar 05, 2019: Medigene publishes preliminary financial results for the financial year 2018
Feb 28, 2019: Medigene presents poster on in vitro evaluation of TCR efficacy and toxicity at AACR
Feb 25, 2019: Medigene: European Patent covering TCR library suitable for the development of neoantigen-specific TCRs
Feb 11, 2019: Medigene appoints Axel-Sven Malkomes as CFO/CBDO
Jan 17, 2019: Medigene participates at four upcoming conferences

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

MediGene AG, Key Facts
MediGene AG, Key Employees
MediGene AG, Key Employee Biographies
MediGene AG, Major Products and Services
MediGene AG, History
MediGene AG, Subsidiaries
MediGene AG, Key Competitors
MediGene AG, Ratios based on current share price
MediGene AG, Annual Ratios
MediGene AG, Annual Ratios (Cont...1)
MediGene AG, Interim Ratios
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MediGene AG, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
MediGene AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

MediGene AG, Performance Chart (2014 - 2018)
MediGene AG, Ratio Charts
MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

COMPANIES MENTIONED

Vita 34 AG
Tigo GmbH
Hemispherx Biopharma Inc
Genentech Inc
Celgene GmbH
Ambrilia Biopharma Inc